GlaxoSmithKline has posted double-digit growth - test
This article was originally published in Scrip
GlaxoSmithKline has posted double-digit growth in both its first-quarter turnover and EPS as strong performances from its vaccines business and from emerging markets, Asia and Europe more than offset a slight decline in sales in the US.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.